TP53 and cancer: Importantly, cancers harboring a TP53 mutation often have intact apoptotic pathway components, providing a therapeutic opportunity independent of a TP53 driver mutation, particularly as many cytotoxic drugs primarily act via p53 to induce apoptosis, which can be a point of resistance [174].